Corvus Pharmaceuticals
CRVS
45 hedge funds and large institutions have $237M invested in Corvus Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 9 closing their positions.
156% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 9
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
45% more funds holding
Funds holding: 31 → 45 (+14)
4% more capital invested
Capital invested by funds: $229M → $237M (+$8.07M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$5.01M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$2.89M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.89M |
| 4 |
JP Morgan Chase
New York
|
+$2.37M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$3.1M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$2.74M |
| 3 |
HI
HBK Investments
Dallas,
Texas
|
-$1.74M |
| 4 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
-$1.67M |
| 5 |
BG
BlackRock Group
London,
United Kingdom
|
-$1.55M |
CRVS Hedge Fund Activity: Q2 2016 in Review
45 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q2 2016, worth a combined $237M — up 3.5% from $229M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CRVS positions and 9 closed out — a net gain of 14 holders — while 11 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock Advisors, adding an estimated $5.01M. The largest seller was Scopia Capital Management, exiting entirely with an estimated $3.1M sold.
- 45 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q2 2016, up from 31 in Q1 2016.
- Funds reported $237M of Corvus Pharmaceuticals stock for Q2 2016, up 3.5% quarter-over-quarter.
- 23 funds opened new Corvus Pharmaceuticals positions in Q2 2016 and 9 closed out, a net change of +14 holders.
- The largest Corvus Pharmaceuticals buyer in Q2 2016 was BlackRock Advisors, an estimated $5.01M added.
- The largest Corvus Pharmaceuticals seller in Q2 2016 was Scopia Capital Management, an estimated $3.1M sold.
Based on aggregated 13F filings for Q2 2016.